Fintel on MSN2d
TD Cowen Initiates Coverage of CG Oncology (CGON) with Buy Recommendation
Fintel reports that on January 7, 2025, TD Cowen initiated coverage of CG Oncology (NasdaqGS:CGON) with a Buy recommendation.
CG Oncology initiated with a Buy at TD Cowen
TD Cowen analyst Tyler Van Buren initiated coverage of CG Oncology (CGON) with a Buy rating and no price target The firm says cretostimogene ...
TD Cowen Begins Coverage on CG Oncology (NASDAQ:CGON)
Investment analysts at TD Cowen began coverage on shares of CG Oncology (NASDAQ:CGON – Get Free Report) in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. The ...
CG Oncology, Inc. (CGON) Receives a Buy from TD Cowen
CG Oncology, Inc. (CGON – Research Report) received a Buy rating and price target from TD Cowen analyst Tyler Van Buren today. The company’s ...
Nasdaq24d
CG Oncology Closes $238 Million Public Offering of Common Stock
CG Oncology closed a public offering of 9.2 million shares, raising $238 million for bladder cancer therapy development. CG Oncology, Inc., a clinical biopharmaceutical company specializing in ...
Nasdaq28d
CG Oncology Announces Pricing of Public Offering for 8 Million Shares of Common Stock at $28 Per Share
CG Oncology announces public offering of 8,000,000 shares at $28 each, expected to raise $204.4 million. CG Oncology, Inc. has announced the pricing of its public offering of 8 million shares of ...
CG Oncology (NASDAQ:CGON) Stock Price Down 6.9% – Time to Sell?
CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) shares were down 6.9% during mid-day trading on Monday . The stock traded as low as $27.84 and last traded at $27.98. Approximately 108,925 shares ...
Seeking Alpha27d
CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene
CG Oncology, Inc. (NASDAQ:CGON) reported positive results just about a week ago from its phase 3 BOND-003 study using its oncolytic immunotherapy candidate Cretostimogene for the treatment of BCG ...
Benzinga.com1mon
Why CG Oncology (CGON) Stock Is Down 9%
CG Oncology shares are trading lower by 9.2% during Wednesday's session. The company announced it filed an underwritten public offering of 7.3 million shares of its common stock. Discover Fast ...
Morningstar24d
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
IRVINE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone ...
Yahoo Finance28d
CG Oncology Announces Pricing of Public Offering
CG Oncology Inc. IRVINE, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a ...
Wall Street Journal3d
CG Oncology Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...